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Abstract: 
Olanzapine (OLZ) is an atypical antipsychotic  agent is and different antipsychotic agent  medications like 
Carbamazepine, Fluoxetine hydrochloride, Simvastatin, Clozapine, paliperidone, Quetiapine, several beta blocker, 
Risperidone, 9-Hydroxyrisiperidone, Demethylolanzapine, Aripiprazole, Orphenadrine, 1,2 Naphthoquinone, P-
dimethylamino Benzaldehyde, Cerium sulphate, N-bromosulphinimide. The present investigation assesses the 
various approaches for analysis of OLZ in bulk drug as well as their pharmaceutical formulations. A concise survey 
states the collection and outline of about 74 explanatory strategies which incorporates HPLC, HPTLC, UV-
Spectrophotometry, electrochemical techniques, LC-MS/MS, techniques actualized for examination of OLZ in 
biological matrices, bulk samples and in different dosage forms. The review depicts the rate usage of the different 
methodologies for examination of OLZ. The measurable information concerning the utility of these strategies for 
estimation of OLZ distributed during 1995 to 2018 have been incorporated. 
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INTRODUCTION: 
Olanzapine (OLZ) is an atypical antipsychotic  agent 
and chemically it is (2-methyl-4-(4-methyl-1-
piperazinyl)-10H-thieno [2, 3-b] [1, 5] 
benzodiazepine) is an (figure 1).[1] It has 
antipsychotic activity and the usual dose is 10 mg 
once daily and it is a white to off-white powder  OLZ 
It is used in the treatment of depression. [2]. 
Additionally, OLZ It decreases the gluconeogenesis 
while increasing the glucose uptake by muscles and 
fat cells. Olanzapine Works by blocking the receptors 
in the brain that are involved in transmitting these 
messages between the nerve cells. [3]. It has a higher 
affinity for 5-HT2 serotonin receptors than D2 
dopamine receptors. OLZ is extensively metabolised 
to form 10-N-glucuronide, 4′-N-desmethyl, 2-
hydroxymethyl and 4′-N-oxide metabolites. Reacts 
with glucuronyltransferase to form a 10-N-
glucuronide and a quaternary 4′-Nglucuronide. The 
cytochrome P450 (CYP) and (FMO) are responsible 
for OLZ metabolism. CYP1A2 and FMO3 form 4′-N-
desmethyl olanzapine and olanzapine Noxide, 
respectively (Figure 2).The average concentrations 
of olanzapine 10-N-glucuronide and N-desmethyl 
olanzapine. 2-Hydroxymethyl olanzapine is a minor 
metabolite and is primarily formed by CYP2D6. John 
T. Callaghan, Richard F. Bergstrom, Louis R. Ptak, 
and Charles M. Beasley 
OLZ  is also available in combination with The OLZ 
in various dosage forms as single constituent and in 
combination with Carbamazepine, Fluoxetine 
hydrochloride, Simvastatin, Clozapine, paliperidone, 
Quetiapine, several beta blocker, Risperidone, 9-
Hydroxyrisiperidone, Demethylolanzapine, 
Aripiprazole, Orphenadrine, 1,2 Naphthoquinone, P-
dimethylamino Benzaldehyde, Cerium sulphate, N-
bromosulphinimide. Although reviews about the 
pharmacology of OLZ have been earlier available, 
none of these reviews concentrated on OLZ analytical 
methods, perhaps because it is one of the bisystolic 
drug introduced in the market. The aim of this review 
is to deliver summary of the relevant published 
literature and a discussion of methods for the 
determination of OLZ on its own or in mixtures, in 
pure form, formulations, and biological samples 
using different analytical procedures (HPLC, 
HPTLC, UV, Bio analytical, LC-MS/MS, etc) 
An extensive literature survey was done using the 
database like scholar, scifinder, Pubmed, Scopus and 
web of science. The literature survey revealed that the 
numerous analytical methods have been reported for 
OLZ such as high-performance liquid-
chromatography, high-performance thin-layer 
chromatography, and Liquid chromatography coupled 
with mass spectrophotometry, ultraviolet and visible 
spectrophotometry. [1-74]. Therefore, the aim of the 
proposed work to analysed and summarized all the 
analytical method exemplified in the literature. 
Taking into account of applicability of OLZ in the 
treatment of Antipsychotic. This analytical profile of 
OLZ focuses the analytical methods for 
determination and quantification of OLZ in 
pharmaceutical formulation as well as in biological 
samples as stated in the literature. Additionally, this 
review focuses on only the methods reported in the 
period of 1995- 2018. 
 
 
Figure 1.Chemical Structure of OLZ 
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Metabolites of OLZ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Metabolites of OLZ 
 
Pharmacopoeial status: 
OLZ is the official drug in Indian Pharmacopoeia (IP) 
- 2007, Indian Pharmacopoeia (IP) – 2010, Indian 
Pharmacopoeia (IP) – 2014, the Merck index 
Thirteenth edition, the Merck index fourteen editions 
and Martindale. 
IP depicted HPLC assay method using C18 (25 cm × 
4.6 mm, 5μm) column as a stationary phase and 
mobile phase consisted of 3gm of ammonium 
dihydrogen orthophosphate adjust pH to 2.5, water 
and triethylamine (70:30 v/v) with a flow rate of 1 
mL/min. Column effluent was monitored at 220 nm 
[5].  
 
IP depicted HPLC assay method using C18 (25 cm × 
4.6 mm, 5μm) column as a stationary phase and 
mobile phase consisted of 3gm of ammonium 
dihydrogen orthophosphate adjust pH to 2.5, water 
and triethylamine, Methanol (70:30 v/v) with a flow 
rate of 1 mL/min. Column effluent was monitored at 
220 nm [6].  
 
IP depicted HPLC assay method using C18 (25 cm × 
4.6 mm, 5μm) column as a stationary phase and 
mobile phase consisted of 4.83gm of sodium 
dihydrogen orthophosphate monohydrate adjust pH 
to 6.8, Acetonitrile and Methanol (80:20 v/v) with a 
flow rate of 1.2 mL/min. Column effluent was 
monitored at 230 nm [7].  
 
BP depicted HPLC assay method using C18 (25 cm × 
4.6 mm, 5μm) column as a stationary phase and 
mobile phase consisted of 0.345%w/v sodium 
dihydrogen phosphate monohydrate adjusted to pH 
6.8 with dilute sodium hydroxide.buffer,Acetonitrile 
and Methanol (25:75v/v) with a flow rate of 2 
mL/min. Column effluent was monitored at 250 nm 
[8]. 
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Analytical Methods for OLZ determination of 
HPLC Method: 
Various separation techniques such HPLC have been 
employed for the determination of OLZ in 
pharmaceutical matrix as well as in biological 
samples. But, HPLC technique was mostly utilized 
for determination of OLZ. Most of the researchers 
utilized C18 reverse phase analytical column for 
separation of OLZ.     
 
Maximum analytical studies with HPLC employed 
for determination of OLZ in pharmaceutical 
formulation on C18 reverse phase analytical columns. 
Water and Methanol in the ratio of 30:70 v/v or 70:30 
v/v mixture as a mobile phase, associated or not with 
some organic additives such as buffers, acids or 
bases, methanol to improve selectivity and 
separation. The wavelength was used in HPLC 
methods ranges from 220-295 nm but in general it 
was set at 235 nm. The data related to simultaneous 
determination of drugs was specified in Table 1 [9-
18].  
 
HPLC Simultaneous method development: 
Mahmoud A Tantawy et al. (2012) A 
spectrophotometry sensitive, accurate, & precise. 
TLC spectrodensitometry & HPLC method for 
simultaneous determined for OLZ & FLU-HCl. two 
spectrophotometry techniques developed first 
derivative (D1) & derivative ratio (DD1). The 
precoated aluminium TLC plate with silica gel 
GF254 Stationary Phase & mobile phase mixture 
methanol: toluene: ammonia (7:3:0:1v/v/v) 
chromatogram wavelength at 235 nm.The HPLC 
developed methods used RP-C18 column with 
isocratic elution. The mobile phase mixture 
Acetonitrile: triethylamine (53:47:0.03v/v/v) pH 
adjusted 4 & flow Rate was found to be about 
1.0ml/min.  The wavelength at 235 nm. [11]. 
 
C. Vitorino et al. (2013) The RP-HPLC method 
developed by the Simultaneous determinate for SA, 
prodrug & the respective active hydroxy acid, SA & 
OZL in dosage form. Containing coencapsulating-
Nanostructured lipid carries. The chromatography 
separation was carried by Phenomenex Luna phenyl-
hexyl column, (5µm,150× 3 mm) temperature at 
35ºC, & Socratic Conditions Used wavelength at 230 
nm.The mobile phase mixture ammonium acetate 
aqueous solution 0.02M, methanol and Acetonitrile 
(30:35:35v/v/v) and flow rate was found to be about 
0.8ml/min. The linear regression analysis, calibration 
curve good concentration range was found to be 0.5-
100µg/mL, r2=0. 9994 for all three compounds, SA, 
OLZ. [12]. 
 
Table 1. Simultaneous estimation of drugs by HPLC 
Sr 
no 
Name of 
drug/ 
formulati
on. 
Column Mobile Phase 
Composition 
Detection  
(nm) 
Detector 
Linearity 
Retention 
Time 
Flow 
rate 
(ml/min) 
Ref 
1 OLZ+FL
U HCl 
Tablet 
Inertsil 
C18 ODS 
column 
Acetonitrile: Methanol 
(90:10V/V) 
UV detector 
233 
20-80µg/ml 
2.7min For 
Fluoxentine 
HCl and 3.3min 
1 9 
2 OLZ + 
FLU HCl 
Tablet 
C18 
column 
Acetonitrile: methanol: 
0.032 M ammonium 
acetate buffer 
(45:05:50V/V/V) 
 
UV/Visible 
detector 
235  
0.2-4µg/ml 
0.1-2 μg/ml 
300–1000 - 
150–500 ng 
1.95.min 
1.5 
 
10 
3 OLZ + 
FLU 
Capsule 
 
Zorbax 
ODS 
column 
C18 
column 
Phosphate buffer pH 
4.0:acetonitrile:triethylam
inen(53:47:0.03V/V/V) 
UV detector 
235  
20–100 ug/mL. 
100–600 
ug/mL. 
2.74, 9.77min. 
1.0  11 
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4 OLZ +SA Luna 
Phenyl 
Hexyl,c18 
column 
Ammonium acetate 
aqueous solution 
0.02Mmethanol:Acetonitr
ile (30:35:35 V/V/V) 
UV/visible 
detector 
230  
0.5-100 μg/mL 
7 min 
0.8  12 
5 OLZ+CL
Z+QUE 
Several 
beta-
blockers 
RP-4 ADS 
column 
Ethanol : water (80:20 
V/V) 
PDA 
Detector 
215 
20-80 μg/ml 
10.89 min 
 
1 
 
13 
6 OLZ+FL
U HCl 
Tablet 
C18 
column 
Acetonitrile: pot. 
Dihydrogen phosphate 
buffer: trietythimine 
(0.2%) (0.1%v/v ortho 
phosphoric acid PH3.1) 
(40:60:02V/V/V) 
UV detector 
233  
10 - 60µg/ml 
20-120µg/ml 
1.96&1.59min 
1.0 
 
14 
7 OLZ 
+FLU 
Tablet 
C18 
column 
75mM potassium 
dihydrogen phosphate 
buffer (pH4.0): 
Acetonitrile: methanol 
(55:40:5V/V/V) 
UV /visible 
detector   
227  
5–80μg/mL 
& 20–320 
μg/mL 
 
0.8 
 
15 
8 OLZ+FL
U HCl 
Tablet 
HYPERSI
L ODS 
C18 
column 
0.01M Phosphate buffer 
PH 5.8: Acetonitrile 
(55:45V/V) pH-2.6 
adjusted with 
Orthophosphoric acid) 
PDA detector 
261  
18-42μg/ml 
and 
72-168μg/ml. 
3.480 and 2.597 
min 
1 
 
16 
9 OLZ+FL
U  HCl 
Tablet 
 
 
C8 
column 
0.1%v/v Ortho 
Phosphoric acid in water 
(pH 3.5 With 
Triethylamine):Acetonitril
e: Methanol 
(60:30:10V/V/V) 
PDA detector 
225 
12-28μg/ml 
48-112μg/ml 
2.19 min and 
3.71. 
1.0  17 
10 OLZ 
Tablet 
Inertsil 
C18 
column 
9.5 mM sodium 
dihydrogen phosphate 
(pH adjusted to 6.8 ± 0.1 
with triethylamine) : 
Acetonitrile : methanol 
 (40:30:30 V/V/V) 
PDA detector 
225  
25 -75 
µg/mL 
100–300 µg/mL 
10 min 
 
1.2  
 
18 
 
HPLC method indicating stability study, impurity 
profiling methods 
Ramisetti Nageswara Rao et al. (2008) The 
simultaneous determination of OLZ by RP- HPLC 
method. A process impurity in bulk drug & tablet 
dosage form was developed. The separation was 
accomplished on Inertsil ODS 3V column (4.6mm, 
250mm, 5µm). The mobile phase mixture of 0.2M 
ammonium acetate (pH= 4. 50): ACN in gradient 
elution mode. The analysis was PDA detector 
wavelength at 254 nm. The flow rate was found to be 
1.0ml/min. [21]. 
 
Table 2. HPLC method indicating stability study, impurity profiling for OLZ 
Sr 
no 
Name of drug/ 
formulation. 
Column Mobile Phase 
Composition 
Detection 
(nm) 
Detector 
Linearity 
Retention Time 
Flow 
rate 
(ml/min) 
Ref 
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11 OLZ Bulk Inertsil C18 
column 
Ammonium 
phosphate buffer : 
methanol (70:30 
v/v) 
UV-Visible 
detector SPD 
10 
220 
2 - 10μg/ml 
3.447min 
1 19 
12 OLZ+CMZP 
Tablet 
ACE5–CN 
column 
Phosphate buffer 
(pH 5.0 25 mM) : 
methanol (80:20 
v/v) (70:30 v/v) 
UV/DAD 
detector 
254 
0.2–50.0 mg/mL 
 
1 
 
20 
13 OLZ 
Tablet 
Inertsil 
ODS 3V 
column 
Water: methanol 
(30:70v/v). 
PDA detector 
254 
10 - 300 µg/mL 
 
1.0 21 
14 OLZ 
Tablet 
Intersil 
ODS 
column 
Ammonium 
acetate 
(pH4.5):Acetonitr
ile 
(70:30v/v) 
PDA detector 
UV detector 
271 
10-200 mg/mL 
7.48 min 
0.5 22 
 
 
 
15 OLZ 
Tablet 
C18  
column 
Potassium 
dihydrogen 
phosphate Buffer 
(pH 
6):Acetonitrile 
(60:40) (v/v) 
UV detector 
258 
5-25 μg/ml 
5 min 
1 
 
23 
16 OLZ +PAL 
Bulk 
C18, YMC 
packpro 
C18, 
Inertsil 
ODS 3V 
0.1%Ammonium 
Acetate in water : 
Acetonitrile  (95:5 
v/v) 
PDA detector 
254 
0.2 mg/ml and 
0.5mg/ml 
0.2 mg/ml and 
0.5 mg/ml 
0.8 
 
24 
17 OLZ 
Bulk 
Agilent 
Octyldecyl 
silica 
column 
(TC-C18, 
Methanol: 0.3% 
TEA in water 
(36 : 64 v/v) 
UV/Visible 
detector 
254 
50 mg ml - 320 
mg/ml 
11.10 time /min 
1.0 
 
25 
18 OLZ 
Tablets 
Kromasil 
C-18 
column 
Acetonitrile: 
phosphate buffer 
 (30 : 70 v/v) 
DAD 
258 
10 - 50 μg /mL 
1.850 min 
1.5 26 
19 OLZ 
Tablet 
BDS 
Hypersil 
C18 
Column 
 
 
0.01M Tetra butyl 
ammonium 
hydrogen 
sulphate: 
Methanol (60:40 
v/v). 
UV Detector 
228 
10-80μg/ml 
10.0 min. 
 
 
 
1.0 
 
27 
20 OLZ Bulk and 
Tablet 
Intersil 
ODS 3V 
column 
10mM disodium 
hydrogen 
phosphate buffer 
(pH 7.4) : 
Acetonitrile (35 : 
UV/ visible 
detector 
254 
2.5–20.0 µg/mL 
4.39 ± 0.01min 
1.0 
 
28 
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65v/v) 
21 OLZ Tablet ODS A-
132 C18 
column 
phosphate buffer 
(pH: 5.5): 
Acetonitrile (7:3 
v/v) 
DAD 
295 
1.61×106 - 
7.24×104 min 
 
1.3 
 
29 
 
Bio-analytical Method: 
The Bioanalytical Method development in Table 3 
Christoph Hiemke et al. (2001) A simultaneous 
technique of the antipsychotic drug CLZ, OLZ, & 
demethylated metabolites. Method included 
adsorption CPS coated clean up column washes & 
interfering serum constituents to waste separation on 
ODS Hypersil C18 column RP- material (5 µm, 250 
× 4.6 mm). A used mobile phase mixture of 
Acetonitrile: water: tetra methyl ethylene diamine 
(37:62.6.4v/v/v) pH adjusted 6.5 concentrated acetic 
acid. The UV detection Lamda max at 254 nm. The 
LOQ was found to be 10-20ng/ml. Relative standard 
variation ranges between 4.5 and 13.5 [33]. 
Huande Li et al. (2012) sensitive, rapid LC-MS/MS 
technique coupled with column developed for the 
determined of OLZ in rat brain microdialysates. The 
both columns C8 guard column used samples before 
analysis separate on a C18 column & detection with 
tandem mass spectrometry. The both mobile phase 
mixtures of methanol: Acetonitrile: water 
(43:43:14v/v/v) was for analysis separated, water in 
both mobile phases contained 0.1% ammonium 
acetate. The LOQ for OLZ was found to be 
0.085ng/ml. The linear from LOQ to 34ng/ml with a 
coefficient of determination more than 0.998. 
Precision study Intraday and interday& accuracy 
were determined with variability less than 13.24% 
(RSD). [35]. 
M. a. raggi et al. (2001) The HPLC method with 
electrochemical detection has been developed for the 
determination of olanzapine and its main metabolite, 
desmethylolanzapine, in human plasma. 
Chromatographies separation and analysis was 
performed on a C8 reversed phase column with a 
mixture of methanol, Acetonitrile, and pH 3.7 
phosphate buffer as mobile phase, 2-
methylolanzapine was used as internal standard. The 
response was linearly dependent on concentration and 
precision were satisfactory over the concentration 
range 0.5-75.0ng/ml for both analytes. The limit of 
detection was 0.2ng/ml for both analytes. [36]. 
Table 3.Bioanalytical paper 
Sr 
no 
Name of 
drug 
Sample 
matrix 
Column Mobile phase 
composition 
Detection 
(nm) 
detector  
Flow 
rate 
(ml/min) 
Ref Internal 
standard 
1 OLZ+ RIS+ 
9-HYD RIS 
Human 
Plasma 
RP18 
column 
10 mM 
ammonium acetate 
buffer at a pH of 
3.5 which was 
adjusted with 
acetic acid : 
Acetonitrile 
(70:30v/v) 
PDA detector    
277 
0.3 30 Clozapine 
 
 
 
 
2 OLZ Human 
Plasma 
YMC 
column 
75 mM sodium 
phosphate (pH 7) : 
methanol: 
Acetonitrile 
(48:26:26 v/v/v). 
Electrochemic
al detection 
1.2 31 Olanzapin
e 
 
3 OLZ Rat Plasma column 
C18hypers
il-BDS 
50 mM phosphate 
buffer pH 5.5: 
Acetonitrile : 
methanol 
UV detector 
214 
1.2 32 Olanzapin
e 
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(50:30:20 v/v/v)  
4 OLZ Human 
Breast Milk 
YMC 
basic 
column 
75mM phosphate 
buffer pH 7.0: 
acetonitrile : 
methanol 
(48:26:26v/v/v) 
Electrochemic
al detection 
1 
 
33 Olanzapin
e 
 
 
5 OLZ Serum Normal-
phase 
silica gel 
column 
50 mM 
ammonium acetate 
buffer adjusted to 
pH 9.9 with 
ammonia water: 
methanol 
(15:85v/v). 
UV detector 
270 
1.1 
 
34 Trifluoper
azine 
 
 
6 OLZ+CLZ Serum C18 ODS 
Hypersil 
Acetonitrile : 
water tetramethyl 
ethylene 
diamine(37:62.6:0.
4 v/v/v) 
UV detector 
254 
1.5 35 Olanzapin
e and 
demethylo
lanzapine. 
 
7 OLZ+CLZ
+RISP 
QUT 
Rat Brain Macherey
nagel C18 
column 
water (formic 
acid: 2.70 mmol/l 
ammonium 
acetate: 10 
mmol/l) : 
Acetonitrile 
(53:47v/v) 
UV detector 
254 
0.16 36 Olanzapin
e and 
quetiapine 
 
 
8 OLZ Human 
plasma 
C18 
column 
0.06 M 
ammonium 
acetate buffer pH 
5.9 : Acetonitrile : 
methanol (40: 41 
:3 : 7 v/v/v) 
electrochemic
al detector 
0.69 37 Clozapine 
 
9 OLZ Human 
plasma and 
Urine 
Supelcosil 
LC-CN 
column 
10%methanol25%
acetonitrile and 
65% 50 mM 
phosphate buffer 
pH 6.0 
UV detector 
214 
1 
 
38 Olanzapin
e 
 
 
10 OLZ Rat plasma YMC 
basic 
column 
75mM phosphate 
buffer (adjusted to 
pH 7 with 5 M 
Sodium 
hydroxide) : 
Acetonitrile : 
methanol 
(48:26:26 v/v/v) 
electrochemic
al detector 
 
1.2 
 
39 Olanzapin
e 
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11 OLZ Human 
Plasma 
Spherisorb 
S5 C6 
analytical 
column 
Water : 
Acetonitrile 
(55:45 v/v) 
UV-VIS 
detector 
254 
 
1.0 40 Clozapine 
 
 
12 OLZ Human 
Plasma 
C 18 
column 
14% acetonitrile in 
water (containing 
0.25% H PO and 
0.05% 
triethylamine) 
electrochemic
al detectors 
270 
1 
 
41 N-
desmethyl
clozapine 
 
13 OLZ+DES
MOLZ 
 
Human 
Plasma 
C8 
column 
Methanol(11%o),a
cetonitrile(9.7%), 
and 8.9mmol L 1 
phosphate 
buffer(79.3%)cont
aining 7.18mmolL 
1 
Triethylamine 
Decade 
amperometric 
detectors 
316 
0.7 
 
42 Methylola
nzapine 
 
14 OLZ Human 
Plasma 
column C8 Acetonitrile:13.5m
M, pH 2.0 
phosphate buffer 
(30:70 v/v pH = 
2.5) 
UV detector 
260 
1 
 
43 Tripralidin
e 
 
15 OLZ+ARI Human 
plasma 
column 
Rp-18 
Phosphate buffer 
(pH 3.14, 20 mM) 
and acetonitrile 
Diode array 
detector. 
255 
0.8 
 
44 Carbamaz
epine 
 
 
 
Spectrophotometric method: 
Spectrophotometric methods with UV-Visible 
detection have been developed for OLZ analysis 
without combination illustrated in Table 4, 5, 6 [45-
62].  
Kishanta Kumar Pradhan et al. (2014) The 
Olanzapine in pure and tablet form. The simple, 
specific and reliable UV-VIS spectrophotometry 
method was studied. The bulk forms mobile phase 
mixture of water: hydrochloric acid (9:1). The Lamda 
max at 258 nm. The regression equation and 
calibration graph, respectively. The concentration 
range of 5-40µg/ml. The correlation coefficient was 
found = 0.059x + 0.171 and 0.998 respectively [45]. 
S.firdous et al. (2005) The determination of 
olanzapine, based on UV spectrophotometry new 
method and non- aqueous titration, has been 
developed. The Lamda max at 226 nm. In a 
methanolic solution of olanzapine. The concentration 
range was found to be 0.1g/ml to 50g/ml beers law 
obeys and interday precision of UV is 0.97%. The 
non-aqueous titration was carried by olanzapine with 
0.1N Perchloricacid. Using naphthobenzene as 
indicators and Intraday precision ranges 0.35%. [50]. 
Sahar R. Fadhel et al. (2016) The new 
spectrophotometric techniques have been developed 
for the assay of olanzapine in bulk and tablet forms. 
This both methods, in acidic medium based on the 
diazocouping of olanzapine and diazotized p-
Nitroaniline to form a stable brown colored water-
soluble azo dye. The maximum Lamda max at 405 
nm. The concentration linear range was found to be 
0.5-45.0 µg/ml. 1.5777×104 L. Mol-1. Cm the LOD 
was found to be 0.3148 µg. mL-1 and sandals 
sensitivity values were found to be 0.0198 µg/cm.  
[53]. 
Table 4.  UV- Spectroscopy method 
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Sr.no 
 
Drug Method 
Wavelength  
(nm) 
Matrix Linearity/lod/loq Ref 
1 OLZ UV Spectroscopic 
Method 
258 
Bulk 5-40μg/ml 
LOD=0.4306ug/ml 
LOQ=1.305ug/ml 
45 
2 OLZ Spectrophotometric 
methods 
410 ,620 
Balk 
Formulation 
Using 
Bromocresol 
Green 
0.25-12.5µg/ml and 0.2-
5.0ug/ml 
LOD=0.28and 0.03ug/ml 
LOQ=0.86 and  0.08ug/ml 
46 
3 OLZ UV 
Spectrophotometric 
Methods 
258 ,252  
Bulk 3-18 μg/ml 
and 4-24 μg/ml 
LOD=0.1680and  
0.2018ug/ml 
LOQ=0.5091and  
0.6115ug/ml 
47 
4 OLZ Spectrophotometry 
Methods 
550, 610 
Tablets 2.0 -20µg/ml 
and 1.0- 10 μg mL 
LOD and LOQ=0.37 and 
1.13 μg mL 
0.16 And 0.48 μg mL-1. 
48 
5 OLZ UV 
Spectrophotometric 
method 
270, 304 & 304 
 
Tablets 10-16 μg/ml 
LOD=0.101, 
0.209,0.109ug/ml 
LOQ=0.306, 
0.634,0.332ug/ml 
49 
6 OLZ UV Spectrophotometry  
and non-aqueous 
titration 
226 
Tablet 0.1 - 50ug/ml 
0.2 - 100mg/m 
LOD=0.1ug/ml,0.3mg 
 
 
 
50 
7 OLZ Spectrophotometric 
methods 
222, 230  
 
Bulk 2-10 μg/ml 
LOD=500ug/ml & 
499ug/ml 
LOQ=166.6ug/ml & 
159.2ug/ml 
51 
8 OLZ Highly sensitive 
Spectrophotometric 
method 
610 
Bulk 0.3 - 8.0ug/ml 
LOD=0.1290ug/ml 
LOQ=0.3696ug/ml 
52 
9 OLZ Spectrophotometric 
method 
405 
Bulk 0.4 – 45ug/ml 
LOD=0.3148ug/ml 
LOQ=1.0495ug/ml 
53 
 
Simultaneous method development 
Farzana I Ghanchivhora et al. (2017) The 
spectrophotometry techniques simple, specific, 
accurate, precise and economical has been developed 
for the both drug olanzapine and paliperidone in 
synthetic mixture. The olanzapine maximum Lamda 
max at 259 NM & paliperidone maximum Lamda 
max at 269 nm. The concentration liner range of 
olanzapine 2-12 µg/ml and paliperidone range 3-18 
µg/ml [57]. 
 
Table 5. Simultaneous UV- Spectroscopy method 
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Analysis with combination drug 
HD Revanasiddappa et al. (2012) The spectrophotometry method simple, sensitivity determined by OLZ &ORPDN 
bulk dosage form. The method developed is based on the ternary complex formulation of drugs under investigation 
with Essen and lead (II) by using methyl cellulose as a surfactant. The maximum wavelength at 540 nm both drug 
OLZ & ORPDN. The optimum experimental conditions for the ternary complex formulation established. The both 
methods obeys bees law concentration range was found to be 0.0-35.0 and 0.0-55 µg/ml. [58]. 
 
 
 
 
 
 
 
 
 
Table 6. UV – Spectroscopy with combination drug 
 
Sr.
no 
 
Drug Method 
Wavelength  
(nm) 
Matrix Linearity 
Lod/Loq 
Ref 
10 
 
OLZ+FLU HCl Simultaneous 
Methods 
318,239 
Bulk 10 - 60 mg/ml 
LOQ=  0.73 to 1.49 mg/ ml and  
0.18 to 0.96 mg/ ml 
54 
11 OLZ+CLOZ+
QUES+several 
beta-blockers 
Simultaneous 
Methods 
215, 226, 242 
and 299. 
 
Tablet 20-80 µg/ml 
LOQ=2.5µg/ml 
LOD=2.50 µg/ml 
55 
12 
 
OLZ+FLU HCl Simultaneous 
method 
226,258  
Bulk 10-100 μg/ml 
10-100 μg/ml 
LOD=1-10 μg/ml 
LOQ=10-50 μg/ml 
56 
13 OLZ+ PAL Simultaneous 
method 
269, 259 
Bulk 3-18 μg/ml and 2-12 μg/ml 
LOD=0.2131 0.645µg/ml 
LOQ=0.218 0.662µg/ml 
57 
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High-performance thin layer chromatography 
(HPTLC): 
The HPTLC technique overcomes the limits of TLC 
as well as takes advantage over the HPLC techniques. 
It shows the advantages like less time consuming, 
Sr.no 
 
Drug Method 
Wavelength 
 (nm) 
Matrix Linearity/lod/loq Ref 
14 OLZ +ORPHE Sensitive 
Spectrophotometric 
Method 
540  
Bulk 0.0-35.0µg/ml and 0.0-55 
μg/mL 
LOD=0.4547 and 
0.9422µg/ml 
LOQ= 0.1501 and 
0.3109 µg/ml 
  
 
58 
 
15 OLZ+ 1,2 
NAPTHOQUI 
-4 SUL (NQS) 
Spectrophotometric 
method 
454 
Tablet 0.4 - 4.0µg/ml 
LOD=0.09µg/ml 
LOQ=0.29µg/ml 
59 
 
 
16 OLZ +P- 
DIMETHYL 
AMINO 
BENZ 
Spectrophotometric 
method 
410  
Bulk 5–160µg/ml 
LOD=6.6µg/ml 
LOQ=20µg/ml 
60 
17 OLZ +CER 
(IV) SUL 
Visible Spectrophotometry 
480, 640, 700 
Tablets 0.2-2.0µg/ml0.5-9.0µg/ml 
0.2- 3.0µg/ml 
LOD=0.01, 0.04, 0.01µg/ml 
LOQ=0.02, 0.11, 
0.03µg/ml 
61 
18 OLZ+ N 
BROMO 
SUSSIMIDE 
+CERB(IV)S
UL 
Spectrophotometric 
method 
532, 538 ,538 
Bulk 10 – 120µg/ml 0.5 – 
6.0µg/ml 0.6 – 3.0µg/ml 
LOD=2.10ug/ml 0.10µg/ml  
0.16µg/ml 
LOQ=6.99µg/ml 0.30µg/ml  
0.37µg/ml 
62 
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cheap, utilizes disposable stationary phases, less 
sample required compared to TLC, gives static and 
offline detection ability and high throughput 
qualitative and quantitative detection. The analytical 
information about HPTLC illustrated in Table 7 [63-
66]. 
  
Sejal Patel et al. (2009) The two different techniques 
a binary mixture of fluoxentine Hcl and olanzapine. 
The first method RP-HPLC determined of 
fluoxentine Hcl and olanzapine. The mobile phase 
mixture of Acetonitrile: methanol: 0.032 M 
ammonium acetate buffer (45:05:50, v/v/v). The flow 
rate was found to be 1.5ml/min. Lambda max at 235 
nm. The concentration range was found to be 0.2-
4µg/ml and 0.1-2µg/ml. The both drug % recovery 
was found to be 101.16±0.59 and 99.79±0.56%. The 
second method HPTLC the both drugs, separation 
followed by densitometry measured of their spots at 
235nm. The separation carried out by Merck TLC 
aluminium plate of silica gel 60F254. The mobile 
phase mixture of acetone: methanol: triethyleamine 
(5:3:0:5v/v/v). The linearity was found to be in the 
range of 300-1000ng/spot and 150-500ng/spot and % 
recovery were found to be 100.95±0.52 and 
99.31±0.51% for Fluoxetine HCl and olanzapine. 
[65]. 
Table 7. HPTLC determination of OLZ 
 
 
LC-MS/MS method: 
Coupling of HPLC with single MS or MS–MS is 
highly sensitive, able to analyze multicomponent, to 
inspect the specificity of the analysis and most 
reliable method to evaluate active ingredients from 
biological samples. In existing LC/MS/MS 
techniques, ionization of the sample is carried out 
under atmospheric pressure (atmospheric pressure 
ionization (API) which is separated from the high 
vacuum portion of the mass analyzer. Two commonly 
Sr 
no 
Drug Formulat
ion 
Stationary  
Phase 
Plate 
Mobile Phase 
Composition 
Detection in 
(nm) 
linearity Rf Ref 
1 OLZ+
FLU 
Tablet Silica gel 
60F254 
Methanol: 
toluene 
(4:2v/v) 
233 100-800 
ng/spot 
1000-8000 
ng/spot 
0.31±0
.01 
 
63 
2 OLZ+
DUOH
Cl 
Synthe
tic 
Mixtur
e 
Capsule Silica 
gel 60 
F254 
 
Toluene: 
methanol:10% 
ammonia3:1.3:0
.05 
(v/v)acetone: 
methanol: 
triethylamine(5:
3:0.5v/v/v) 
231,  
240  
60–480 ng/spot 
per 
100-800& 
50–400 ng 
0.39 
±0.02 
0.63 
±0.02 
& 0.77 
± 0.02, 
64 
3 OLZ+
FLU 
HCl 
Tablet Silica gel 
60 F254 
Acetone:methan
ol:triethyleamin
e (5:3:0.5 v/v/v) 
235  300–1000 & 
150–500 ng/spot 
_ 65 
4 OLZ Bulk Silica gel 
60F254 
Methanol :ethyl 
acetate (8.0 + 
2.0 v/v) 
285  100 - 600 
ng/band 
Rf = 
0.35 -
0.02 
66 
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used methods of atmospheric pressure ionization 
involve electrospray ionization (ESI) and atmospheric 
pressure chemical ionization (APCI) of the molecules 
to be analyzed. The most use mobile phase was 
10mM aqueous ammonium acetate adjusted to pH 4 
with formic acid and Acetonitrile along with 
methanol. And for analysis of sample generally used 
matrix was Human plasma. The mass to charge ratio 
was used in the range of 313.2-256.3 and extraction 
of samples done by various methods such as protein 
precipitation, liquid-liquid extraction, solid-liquid 
extraction, Serum or cerebral spinal fluid samples, 
ion-exchange cartridges, Rat brain homogenate and 
analyzed etc. The separation was carried out on the 
C18 column generally. The concise analytical data 
related to the LC-MS/MS is depicted in Table 8 [67-
82].  
 
Michael G. Bartlett et al. (2007) The analytical 
method extract from rat brain homogenate and 
analyzed by LC-MS/MS. sample prepared and 
chromatography study, he method used a Water 
Atlantis TM dC-18 column (30mm×2.1mm 3mm). 
Gradient elution the mobile phase mixture of 
Acetonitrile: 5mM ammonium Formate adjusted 
pH6.1 with formic acid. The analytical method in 
positive ion separated used multiple reaction 
monitoring. [68]. 
 
Table 8. LC-MS 
Sr. 
no 
Drug Matrix Extraction 
method 
m/z ratio  LC Separation Lod/Loq Ref 
Column M.P 
1 OLZ Human 
Plasma 
solid phase 
extraction 
m/z 
313/256 
m/z 
384/253 
ACE5 
C18-300 
column 
(5:95,10:90,15:85,20:80 and 
30:70v/v) of water methanol: 
Acetonitrile :  formic acid : 
ammonia(0.010.005%) 
ammonium trifluoroacetate 
ammonium acetate or 
ammonium formate buffer 
sin varying strengths (2–
20mM) 
LOD=0.10&0
.012 
ng/mL 
67 
2 OLZ+RI
SP,9 
HYDR
ORISP+
CLOZ+ 
HOPO 
+ZIPRA
S 
 
Rat Brain 
Tissue 
Rat brain 
homogenae 
and 
analyzed 
m/z 313m/z 
256 32V 23 
eV 
C8 guard 
column. 
100µl of methanol: 20mM 
ammonium formate (pH3.86, 
adjusted by formic acid) 
(70:30v/v). 
LOQ=0.208 
ng/ml 
68 
3 OLZ Human 
Blood 
Liquid–
liquid 
extraction 
(m/z313.42
56.2)327.3
270.1) 
Monochr
m HPLC 
column 
100 mM ammonium acetate: 
methanol: isopropanol: water 
(15:4:1v/v/v). 
 
_ 
 
 
69 
4 OLZ+F
LU 
Human 
Plasma 
Plasma 
samples on 
Waters 
m/z 313, 
310, 
316and 315 
Themo 
Hypersil 
Gold 
C18 
2 mM ammonium acetate: 
Methanol (10:90 v/v) 
LOQ=0.50 
ng/ml 
 
 
70 
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5 OLZ Rabbit 
Plasma 
Liquid-
Liquid 
extraction 
m/z 313.4 
→256.3 
C18 
column 
0.1% v/v formic acid in water 
: Methanol  (08:92 v/v) 
LOQ=5ng/ml 71 
6 OLZ+F
LU 
Human 
Plasma 
Solid phase 
extract on 
m/z 
310.01!147
.69 
313.15!256
.14 
298.1!153.
97 
Gold 
C18colu
mn 
Acetonitrile: water 
containing 2% formic acid 
(70:30v/v) 
LOQ=0.37 
ng/ml 
72 
7 OLZ Human 
Plasma 
Liquid–
liquid and 
SPE 
extraction 
m/z 313.3 
→ 256.1 
YMC-
ODS-AQ 
C18 
Column 
10 mM ammonium acetate in 
water contained 0.05% (v/v) 
formic acid (pH 3.5) 
methanol containing 0.05% 
(v/v) formic 
LOQ=0.2  
ng/ml 
 
 
73 
8 OLZ Human 
Plasma 
Liquid- 
liquid 
extraction 
m/z 313.15 ZORBA
XEclipse 
XDB-CN 
column 
Acetonitrile : aqueous 
ammonium acetate solution 
(pH 4.0, 10 mM) (56:44v/v) 
LOQ=0.5ng/
mL 
74 
9 OLZ Blood Solid-phase 
extraction 
m/z 313 → 
256 
m/z 313 → 
84 
Revered 
phase 
Zorbx 
Extend-
C18colu
mn 
Methanol : Acetonitrile : 
ammonium hydroxide 
(25:25:50 : 5 mM v/v/v) 
 
LOQ=0.005m
g/kg 
75 
10 OLZ+RI
SP+QU
E+CLO
Z+ZIPR
AS+PE
RO+ 
ARIPI 
 
Human 
Serum 
Solid-phase 
extraction 
 
 
 
_ 
Mightysi
l-RP-18 
MS 
column 
10 mM formic ammonium 
buffer (pH 6.0) : Acetonitrile 
LOD=0.0007
1, 0.031, 
0.015, 
0.046, 0.017, 
0.0057, 0.012 
and 
0.027ng/ml 
LOQ=20ng/
ml 
76 
11 OLZ+N
-
DESME
THYL 
OLZ 
Human 
Serum 
and 
Cerebros
pinal 
Fluid 
Serum or 
cerebral 
spinal fluid 
samples 
 
 
_ 
Hydro-
RP 
column 
buffer (10mM 0.05% formic 
acid dilution of 5ml 
ammonium formate stock 
Solution and 250ml formic 
acid (98%) 
LOQ=0.3 
ng/ml& 0.9 
ng/ml 
77 
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CONCLUSION: 
The present review illustrates various analytical 
approaches executed for the valuation of OLZ. An 
abundant investigation had performed, including, 
HPLC, Bio-analytical, HPTLC, UV/Vis-
Spectroscopy, LC-MS/MS, GC-MS, etc. for 
estimation of OLZ in bulk and in its combined 
pharmaceutical formulations and in plasma. High 
performance-Liquid chromatography with UV 
detection has been found to be the most studied for 
estimation of OLZ in bulk as well as pharmaceutical 
formulations, while hyphenated LS-MS/MS method 
was reported for determination of OLZ and its 
metabolite in plasma and other biological fluids. 
Further, methods were reported for its 
pharmacokinetics as well as bioequivalence studies. 
Few chromatography approaches like HPTLC and 
Stability-indicating HPLC analysis is also reported in 
the literature. Certain Spectrophometric methods in 
UV-Visible spectroscopy analysis is most often used 
for assessment for OLZ. 
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12 OLZ+D
ESMET
HYL 
OLZ 
Anticoag
ulant and 
lipemia 
Waters 
Oasis MCX 
cartridges 
and 
analyzed 
m/z 
312.9/256.
0 
Phenome
nex 
LUNA 
pheyl 
hexyl,col 
mn 
Acetonitrile: ammonium 
acetate (20 mM) (52:48v/v). 
Formic acid : Acetonitrile 
(0.1:100 v/v). 
 
 
 
_ 
78 
13 OLZ Human 
Urine 
Solid-phase 
extraction 
_ 
 
 
C18 
column 
Ammonium acetate (pH 7.8): 
Acetonitrile (10:90v/v). 
LOQ= 
1ng/ml 
79 
14 OLZ Human 
Plasma 
Liquid–
liquid 
extraction. 
m/z: 313.1 
> 256.1 
278.1 > 
260.2 
ACE 
C18, 
column 
water with 0.1% formic acid 
Acetonitrile :  0.1% formic 
acid (50 : 50 v/v) 
LOQ= 
1ng/ml 
80 
15 OLZ+F
LU+NO
R FLU 
Human 
plasma 
Liquid-
liquid 
extraction 
m/z 313.10 
→256.05,
m/z 310.10 
→148.00,
m/z 296.05 
→133.90 
Agilent 
Eclipse 
Plus C18 
column 
Methanol: 20 mM 
ammonium formate buffer 
(82.5: 17.5 v/v). 
LOQ=0.05 
ng/ml 
 
 
 
 
 
81 
16 OLZ Human 
plasma 
Liquid–
liquid 
extraction 
m/z 
313/256 
Revere 
phase 
C18 
column 
10mM ammonium acetate 
buffer  : Acetonitrile 
(10:90v/v) 
LOQ= 100 
pg/ml 
82 
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Abbreviations: 
 OLZ - Olanzapine 
 FLU- Fluoxetine  
 CLZ- Clozapine 
 CMZP- Carbamazepine 
 PAL- Paliperidone 
 RIS- Risperidone 
 ARI- Aripiprazole 
 ORPHE- Orphenadrine 
 SA- Simvastatin  
 LC-ES/MS/MS- Liquid chromatography 
Electrospray-mass spectroscopy-mass 
spectroscopy  
 GC-MS-MS- Gas chromatography- mass 
spectroscopy-mass spectroscopy  
 LC-MS- Liquid chromatography-mass 
spectroscopy  
 SEM- Simultaneous equation method  
 RF- Retention factor 
 ESI- Electro-spray ionization  
 nm-Nanometer  
  M.P.- Melting point  
  ACM-Absorption correction method  
  ACN- Acetonitrile  
  FA- Formic acid  
  MFE- Mercury film electrode  
  HMDE- Hanging mercury drop electrode  
 CZE- Capillary zone electrophoretic  
  MEKC- Micellar electro kinetic capillary 
chromatographic  
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